Qualigen Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
FFR$0.89+14.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statement of Operations
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| EXPENSES | ||||
| General and administrative | $1,891,108 | $1,145,152 | $5,780,572 | $3,186,575 |
| Research and development | 105,576 | 123,429 | 156,558 | 1,242,101 |
| Credit loss expense - short-term note receivable | (567,000) | — | (99,000) | — |
| Total expenses | 1,429,684 | 1,268,581 | 5,838,130 | 4,428,676 |
| LOSS FROM OPERATIONS | (1,429,684) | (1,268,581) | (5,838,130) | (4,428,676) |
| OTHER EXPENSE (INCOME), NET | ||||
| Loss (Gain) on change in fair value of warrant liabilities | 148,346 | (1,231) | 93,148 | (361,137) |
| Loss on change in fair value of derivative liabilities | — | 495,693 | — | 321,080 |
| Loss on change in fair value of convertible debt | 197,667 | — | 159,793 | — |
| Interest expense | 455,941 | 408,359 | 635,607 | 808,477 |
| Interest income | (193,819) | (48,082) | (449,249) | (48,082) |
| Loss on issuance of convertible debt | — | — | 91,943 | 358,279 |
| Gain on voluntary conversion of convertible debt into common stock | — | 27,790 | — | (56,010) |
| Loss on monthly redemptions of convertible debt into common stock | — | — | — | 208,852 |
| Gain on settlements of accounts payable | — | (348,305) | — | (348,305) |
| Other income, net | — | (6,547) | — | (9,262) |
| Total other expense (income), net | 608,135 | 527,677 | 531,242 | 873,892 |
| LOSS BEFORE (BENEFIT FROM) PROVISION FOR INCOME TAXES | (2,037,819) | (1,796,258) | (6,369,372) | (5,302,568) |
| (BENEFIT FROM) PROVISION FOR INCOME TAXES | — | (2,198) | 35 | 800 |
| NET LOSS FROM CONTINUING OPERATIONS | (2,037,819) | (1,794,060) | (6,369,407) | (5,303,368) |
| DISCONTINUED OPERATIONS | ||||
| Loss on disposal of discontinued operations, net of tax | — | — | — | (100,000) |
| GAIN (LOSS) FROM DISCONTINUED OPERATIONS | — | — | — | (100,000) |
| NET LOSS | (2,037,819) | (1,794,060) | (6,369,407) | (5,403,368) |
| Deemed dividend arising from preferred stock and warrant down-round provision | $(867,796) | $(27,587) | $(869,382) | $(87,604) |
| Net loss attributable to Qualigen Therapeutics, Inc | $(2,905,615) | $(1,821,647) | $(7,238,789) | $(5,490,972) |
| Total net loss per common share, basic and diluted | $(4.68) | $(4.70) | $(4.35) | $(24.93) |
| Weighted-average number of shares outstanding, basic and diluted (after stock split) | 620,694 | 387,878 | 1,662,223 | 220,221 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.